Search Results

CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season - Jul 17, 2023

https://newsroom.csl.com/2023-07-17-CSL-Seqirus-Begins-Shipping-Portfolio-of-Innovative-Influenza-Vaccines-for-the-2023-24-U-S-Season

CSL Seqirus is a global influenza vaccine provider developing innovative solutions.

https://www.csl.com/patients-public-health/vaccines

The results demonstrate that the A(H5N1) sa-mRNA influenza vaccine candidate induced an anti-HA and anti-NA neutralizing response raised by sa-mRNA influenza vaccines at a dose as low as 0.01 μg in mice and also induced HA-specific CD4+ T cells.

https://newsroom.csl.com/2022-10-05-CSL-Announces-Positive-Preclinical-Data-for-Self-Amplifying-Messenger-RNA-sa-mRNA-Influenza-Vaccine-Candidates

In Belgium, where roughly 62% of older adults received a standard-dose egg-based influenza vaccine between 2015-2019, an analysis was conducted to investigate the potential cost effectiveness of using an adjuvanted quadrivalent influenza vaccine (aQIV).

https://newsroom.csl.com/2023-09-18-CSL-Seqirus-Shares-Data-Demonstrating-the-Potential-for-Influenza-Vaccination-to-Reduce-the-Burden-on-Healthcare-Resources

CSL Seqirus has been an active and reliable partner to the UK across pandemic influenza vaccines for many years."

https://newsroom.csl.com/2023-09-26-CSL-Seqirus-secures-multi-year-pandemic-preparedness-agreement-as-part-of-its-continued-partnership-with-the-UK-government

Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine vs High-Dose Influenza Vaccine in Older Adults with Influenza Risk Factors during the 2019-2020 U.S. Influenza Season.

https://newsroom.csl.com/2023-09-15-CSL-Seqirus-to-Present-at-9th-ESWI-Conference-on-the-Burden-of-Influenza-and-Impact-of-Vaccination-on-Public-Health

With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics

CSL Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus/csl-seqirus-manufacturing/csl-seqirus-manufacturing-technologies

We are a diverse collective of people after one goal - to reimagine, reinvent and find new answers that save, improve and protect life.

https://www.csl.com/we-are-csl

The researchers concluded that regardless of the severity of the flu season, preventing any saturation of acute hospital or ICU hospital beds would occur only if the vaccination rate for influenza vaccines was increased to 70 percent or higher.

https://newsroom.csl.com/2022-09-26-New-Data-at-OPTIONS-XI-Conference-Highlight-Burden-of-Seasonal-Influenza-on-Health-Systems-and-the-Need-for-Increased-Vaccination-Rates